Use of any investigational product within weeks prior to randomization Participation in another clinical study with an investigational product during the days prior to first dose of olaparib and temozolomide Concurrent enrollment in another clinical study or receipt of an investigational product within the last weeks (participation in the survival follow-up period of a study is not an exclusion criterion) Active, known, clinically serious infections within the days prior to first dose of investigational product Participation in a clinical study with an investigational product within weeks prior to the start of the study treatment (i.e. D of cycle ) Agree to use condoms until days following the last dose of investigational product, or Participation in another clinical study with an investigational product during the last days Subject has received treatment with any investigational immunotherapy within years prior to study screening or has received treatment with any other investigational product within days prior to study screening Subject who has been treated with an investigational product and has not completed the entire follow-up period for that investigational product; Treatment with any investigational product within days prior to Screening. Radiation therapy within weeks of investigational product. Any other anti cancer agents (eg, hormonal, biological, investigational) within times the half life prior to investigational product. Subjects who have participated in a clinical trial within days of Screening or are scheduled to receive an investigational product. Previous investigational product (IP) assignment in the present study Participation in another clinical study with an investigational product during the last weeks. Administration of another investigational medicinal product within days before the screening period. Participation in another clinical study with an investigational product during the weeks prior to therapy initiation Participation in another clinical study with an investigational product during the last weeks Participation in another clinical study with an investigational product during the last month prior to initiation of therapy Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational medicinal product (IMP) within ? x the half-life of the IMP prior to day cycle of Minnelide. Participation in another clinical study with an investigational product during the last months Participation in another clinical study with an investigational product during the last weeks Participation in another clinical study with an investigational product during the last month Participation in another clinical study with an investigational product administered during the last days. investigational product AGS-CF and/or, Participation in another clinical study with an investigational product during the last weeks Participation in another clinical study with an investigational product during the last weeks (prior use of bevacizumab in the upfront setting is allowed) Patients who are currently participating in any other clinical trial of an investigational product Participation in another clinical study with an investigational product during the last weeks Participation in another clinical study with an investigational product for cancer during the last months Participation in another clinical study with an investigational product during the last months (mo) Hemoglobin >= . g/dL within first weeks prior to first dose of investigational product Patients who are currently participating in any other clinical trial of an investigational product Participation in another clinical study with an investigational product during the last weeks The subject must have no measurable disease at the time of investigational product administration\r\n* The subject must complete all prior surgery requiring general anesthesia at least four () weeks before administration of the investigational product; the subject must complete all surgery requiring local/epidural anesthesia at least seventy-two () hours prior to administration of the investigational product\r\n* The subject must complete all prior systemic chemotherapy therapy, and all adverse events have either returned to baseline or have stabilized at least four () weeks prior to administration of the investigational product\r\n* The subject must complete all prior systemic radiation therapy at least four () weeks prior to administration of the investigational product; the subject must complete all prior focal radiation therapy at least two () weeks prior to the administration of the investigational agent; the subject must not have received a radiopharmaceutical within eight () weeks prior to the administration of the investigational product\r\n* The subject may continue hormonal therapy (i.e. tamoxifen, anastrozole) during the study The subject has a history of anaphylaxis or other serious adverse reactions relating to administration of any components of the investigational product Treatment with an investigational product during the last weeks Participation in another clinical study with an investigational product during the last months Receipt of radiation therapy within weeks prior to starting investigational product, or limited field of radiation for palliation within weeks of the first dose of investigational product Intolerance to the investigational product or its excipients, or any condition that would significantly impair and/or prohibit the patient's participation in the study, as per the Investigator's judgment. Participation in another clinical study with an investigational product (IP) during the last weeks before the first day of study treatment Current or recent treatment with any other investigational medicinal product or device Use of any investigational product within weeks prior to randomization Participation in another clinical study with an investigational product during the last weeks Participation in another clinical study with an investigational product during the last weeks or half-lives prior to starting on treatment. Participation in another clinical study with an investigational product during the last weeks Use of any investigational product within days prior to randomization Treatment with any investigational product during the last days (or a longer period depending on the defined characteristics of the agents used) Investigational medicinal product within the last days prior to screening Investigational medicinal product within the last days prior to screening Treatment with any investigational product within < half-lives for each individual investigational product OR days prior to randomization Patient has an investigational medicinal product within the last days prior to screening. Had chemotherapy or radiotherapy within weeks prior to the first day of Investigational Product (IP) administration. Participation in a therapeutic investigational study within weeks prior to enrollment, or anticipated treatment with another investigational product while on study; this refers to non-commercially approved investigational drugs different than those used in this protocol Participation in another clinical study with an investigational product during the last days Participation in another clinical study with receipt of an investigational product during the last weeks Concurrent enrollment in another therapeutic clinical study or receipt of an investigational product within the last weeks (participation in the survival follow-up period of a study is not an exclusion criterion) Current, or recent (within days, or half-lives of investigational product) participation in other clinical trials of investigational agents and/or containing interventional procedures deemed contrary to the objectives and conduct of this trial. Use of any investigational product or investigational medical device within days prior to enrollment Patient who will be receiving another investigational product during the study The patient has received any investigational therapy ? days prior to start of Investigational Product. Investigational therapy is defined as any medicinal product that is not approved in the country of treatment for any indication, adult or pediatric. Concurrent use of any other investigational product Participation in another clinical study with an investigational product during the last days Participation in another clinical study with receipt of an investigational product during the last weeks Participation in another clinical study with an investigational product during the previous weeks Participation in another clinical study with an investigational product during the last weeks Exposure to an investigational product or investigational device in another clinical study within weeks prior to CD, or is scheduled to participate in another clinical study involving an investigational product or device during the course of this study Participation in a clinical study with an investigational product within weeks prior to the start of the study treatment (i.e., D of Cycle ) Understand that the (investigational Product) IP could have a potential teratogenic risk. Prior treatment with any investigational product within the past weeks Treatment with any investigational product within days prior to signing the ICF. Subjects receiving any other investigational medicinal product or anti-cancer therapy. Participant has been exposed to an investigational product (IP) or investigational device in another clinical study within weeks prior to IP administration, or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study Received an investigational product within days of study treatment or planned to receive within days after vaccine administration The patient has received any investigational or non-registered medicinal product other than the study medi-cation within days preceding the first dose of study medication or plans to receive such a drug during the study period. Participation in another clinical study with an investigational product during the last days Other investigational product-concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited Other medications that might interfere with the evaluation of the investigational product Other investigational product concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited Other medications that might interfere with the evaluation of the investigational product Subjects must be willing to undergo a cystoscopy on study for investigational product removal. Subjects who have received radiotherapy to the pelvis and/or sternum within one year of first Investigational Product administration Less than days since receipt of any investigational product or device. Investigational use/receipt of a medicinal product or device that has been approved by the country's local regulatory authority for any indication is permitted. RECIPIENT: Other investigational product concurrent enrollment in other clinical trials using any investigational new drug (IND) drugs with unknown effects on CMV or with unknown toxicity profiles is prohibited RECIPIENT: Other medications that might interfere with the evaluation of the investigational product Participation in a trial of an investigational medicinal product within the previous days The use of any investigational agent within days preceding the first dose of the study vaccine or subsequent participation in another clinical trial at any time during the study period, in which the subject will be exposed to an investigational product Agree to abstain from breastfeeding during study participation and for at least days after the last dose of IP. Note that the screening serum pregnancy test can also be used as the test prior to starting IP (Investigational Product) if it is performed within the -hour timeframe. Known clinically-significant doubling in marrow or perIP (INVESTIGATIONAL PRODUCT) heral blood blast percentage (to ? %) in the -week period leading to the first dose of IP (INVESTIGATIONAL PRODUCT) (Cycle , Day ) Use of any of the following within days prior to the first dose of IP (INVESTIGATIONAL PRODUCT): Participation in another clinical study with an investigational product during the last days Use of any investigational or non-registered product other than the study vaccine within days preceding the first dose of study vaccine/placebo, or planned use during the study period. However, the investigational use of a registered product to treat the subject's underlying disease, is allowed. Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product. NOTE: Subjects enrolled in this study may also be eligible for a four-year gynaecological follow-up of the HPV- study, in which no investigational product will be administered. Subjects will be invited to the gynaecological follow-up study if either of the following applies: Subject has previously received VM, or any other investigational product in the past thirty days testing on site at the institution (urine or serum HCG) within hours prior to the start of investigational product administration Use of any other investigational product or device within days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments Agrees not to receive any other investigational product or therapy while participating in this study. Participation in another clinical study with an investigational product during the last days Has received an investigational product within the days prior to Lymphoseek administration Patients with the use of any investigational product or device, excluding fluorodopa (F-DOPA) scans, within days prior to dosing May have received treatment with an investigational product. Treatment with any investigational product within days before the first infusion.